Abstract

A NEW DRUG FOR HEART FAILURE: LCZ696

*Dr. Neha Sharma, Dr. Dhruva Sharma, Dr. Saurabh Kohli, Dr. Uma Advani, Dr. Charu Jain, 6Manisha Trivedi

Abstract

Congestive heart failure is a chronic and debilitating disease whose prevalence is 1–2% in the western world and the incidence is 5–10 per 1000 persons per year. Apart from the neurohormonal pathways, the renin-angiotensin-aldosterone system (RAAS) is one of the most potentially beneficial counter-regulatory systems that has now a days become one of the prime focus of therapeutic intervention. A systematic literature search was carried out using databases such as PubMed, Cochrane reviews, Google scholar, etc. And exhaustive information regarding LCZ696 was gathered. The U.S. Food and Drug Administration (US FDA) approved sacubitril/valsartan combination on 7th July, 2015 for the treatment of heart failure and has been given brand name Entresto. US Food and Drug Administration (FDA) granted priority review for LCZ696 on Feb. 13, 2015 and this has reduced the total review time from 12 to 8 months. This sacubitril/valsartan combination comes under the category of "angiotensin receptor-neprilysin inhibitor" (ARNi). Efficacy of LCZ696 in treating heartfailure is based on the PARADIGM-HF trial in which LCZ696 which is a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril was compared with the angiotensin-converting enzyme inhibitor enalapril in 8,442 patients with

Keywords: symptomatic chronic systolic heart failure. LCZ696 may offer a promising role in the treatment of heart failure. ARNi may find its place in the classification of drugs used for the treatment of heart failure. It is under trial for essential hypertension a